(Total Views: 602)
Posted On: 05/26/2020 6:58:56 PM
Post# of 153933
CDiddy,
Exactly. imho NP shouldn't do an interim analysis on the trial unless the enrollment is taking months (rather than weeks).
Personally I have waited years for all this to happen and we are very close to a potential first approval that will open many doors for us.
A coupe of more weeks to get 10 or so more patients will be OK with me. I wrongly predicted that we would have full enrollment by the end of the month, however, is not much more now.
Remember that we need to have EXPECTACULAR results for the FDA to "wake up" to Leronlimab. For what we have seen with our competitors, we will be up here crossing the finish line in the front pack. We kind of need full (or close to full) enrollment to convince with no caveats.
So, let's keep calm. We are almost there.
Exactly. imho NP shouldn't do an interim analysis on the trial unless the enrollment is taking months (rather than weeks).
Personally I have waited years for all this to happen and we are very close to a potential first approval that will open many doors for us.
A coupe of more weeks to get 10 or so more patients will be OK with me. I wrongly predicted that we would have full enrollment by the end of the month, however, is not much more now.
Remember that we need to have EXPECTACULAR results for the FDA to "wake up" to Leronlimab. For what we have seen with our competitors, we will be up here crossing the finish line in the front pack. We kind of need full (or close to full) enrollment to convince with no caveats.
So, let's keep calm. We are almost there.
(6)
(0)
